1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Analysis of Genentech, Inc.

Analysis of Genentech, Inc.

  • March 2015
  • -
  • Aruvian's R'search
  • -
  • 120 pages

Genentech, Inc., an independent subsidiary of Roche Holding, is a leading biotech company headquartered in California, United States. The company's primary focus is on developing drugs for medical conditions such as cancer, angiogenic disorders, immunological diseases and others. Rituxan, Herceptin, Xolair, Activase, etc., are some of the company's major products that are well known around the world.

Aruvian’s R’search presents Analysis of Genentech Inc. A complete and comprehensive analysis of Genentech Inc., includes an overview of the industry the company operates in, a PEST Framework Analysis of the industry, and then moves on to analyzing the company itself.

Company analysis from Aruvian includes a history of Genentech Inc., a business segment analysis of the segments Genentech Inc. operates through, a look at the organization structure of the company, a geographical operating segments analysis, an analysis of the company’s major competitors.

A financial analysis of Genentech Inc. is presented in the report which includes a ratio analysis, basic profit and loss analysis, presentation of the company balance sheet, and much more.

A SWOT Framework Analysis of Genentech Inc. completes this in-depth company analysis.

Table Of Contents

Analysis of Genentech, Inc.
A. Executive Summary

B. Looking at the Industry
B.1 Industry Definition
B.2 Brief Profile of the Industry
B.3 Impacts on the Industry
B.4 Challenges Facing the Industry
B.5 Future Perspective

C. Industry PEST Framework Analysis
C.1 Political Aspects
C.2 Economic Aspects
C.3 Social Aspects
C.4 Technological Aspects

D. Looking at Genentech, Inc.
D.1 Company Profile
D.2 History of the Company
D.3 Organizational Divisions
D.4 Profiling the Key Executives
D.5 Products and Services

E. Looking at Business
E.1 Business Segments
E.2 Geographical Segments
E.3 Company Subsidiaries

F. Genentech Inc.: SWOT Framework Analysis
F.1 Strengths to Build Upon
F.2 Weaknesses to Overcome
F.3 Opportunities to Exploit
F.4 Threats to Overcome

G. Profiling the Competition
G.1 Amgen Inc
G.1.1 Corporate Profile
G.1.2 Business Segment Analysis
G.1.3 Financial Analysis
G.1.4 SWOT Analysis
G.2 Bristol-Myers Squibb Company
G.2.1 Corporate Profile
G.2.2 Business Segment Analysis
G.2.3 Financial Analysis
G.2.4 SWOT Analysis
G.3 GlaxoSmithKline plc
G.3.1 Corporate Profile
G.3.2 Business Segment Analysis
G.3.3 Financial Analysis
G.3.4 SWOT Analysis

H. Genentech, Inc.: Financial Analysis
H.1 Current Financials
H.2 Balance Sheet
H.3 Profit and Loss Statement

I. Genentech, Inc.: Future Perspective

J. Glossary of Terms

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.